You are here: Industry Insights > Pharma in China > Analysis of 39 New Biological Drugs Marketed in the World in 2018

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Avatrombopag Maleate

BioHub® Magnetic Separator

Avatrombopag

Ursodeoxycholic acid

Troxerutin

CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Analysis of 39 New Biological Drugs Marketed in the World in 2018

PharmaSources/XuanyaoFebruary 01, 2019

Tag: Biopharmaceutical , biological drugs , global , 2018

Favorites

21^st century is the century of life sciences. Currently, more than half of members of the United States National Academy of Sciences engage in the life science field; more than half of the U.S. Federal Government’s budget for scientific research is used for life sciences. Therefore, biological drugs are developing faster and faster in human disease therapeutic areas, compared to chemical drugs.

Analysis of 39 New Biological Drugs Marketed in the World in 2018

Biotech drugs are referred to as biological drugs and mainly divided into recombinant protein drugs, recombinant polypeptide drugs, recombinant DNA drugs, and stem cell therapies, etc. It’s estimated that the global biological drug market will reach USD 326 billion in 2022. And Frost&Sullivan forecasts that the Chinese biological drug market will reach a size of RMB 326.9 billion in 2021. Among the 93 new drugs marketed in the world in 2018, there are 54 chemical drugs and 39 biological drugs.

Let’s check the targets and R&D information of those 39 drugs:

S/N	Pharmaceutical product name	Target	R&D company
1	Caplacizumab	vWF	Ablynx
2	Darvadstrocel (TiGenix)	unidentified	TiGenix, Takeda
3	YS-ON-001	unidentified	Yisheng Biopharma
4	Etanercept biosimilar (Mochida)	TNFβ, TNFα	Mochida Pharmaceutical , Ayumi
5	Adalimumab biosimilar	TNFα	Fujifilm Kyowa Kirin Biologics, Mylan
6	Adalimumab biosimilar	TNFα	Sandoz
7	Romosozumab	SO	Amgen, UCB, Astellas
8	Andexanet alfa	PT	Portola Pharmaceutical
9	Pegvaliase-pqpz	Phenylalanine	BioMarin Pharmaceutical
10	Cemiplimab	PD-1	Regeneron Pharmaceuticals , Sanofi
11	Sintilimab	PD-1	Innovent Biologics, Eli Lilly
12	Toripalimab	PD-1	Shanghai Junshi Biosciences, Suzhou Zhonghe
13	Velmanase alfa	Mannose	Zymenex
14	Lanadelumab	KLKB1	Dyax Pharma
15	Meningococcal A/C vaccine (Hualan Biological Bacterin)	Immunostimulator	Hualan Biological Bacterin Co., Ltd.
16	House-dust mite allergy immunotherapy (Lofarma)	Immunomodulator	Lofarma S.p.A, Ajou University School of Medicine
17	tagraxofusp-erzs	IL3RA	Texas A&M University, Stemline
18	Tildrakizumab-asmn	IL23	MSD, Sun Pharmaceutical, Almirall
19	Emapalumab	IFN-γ	NovImmune, SOBI
20	Recombinant cytokine gene derived protein (Genova Biotech)	IFNAR	Genova
21	Trastuzumab biosimilar (Allergan/Amgen)	HER2	Synthon, Allergan, Daiichi Sankyo, Amgen
22	Trastuzumab biosimilar (Pfizer)	HER2	Pfizer
23	Agalsidase beta biosimilar (JCR Pharmaceuticals)	Glycosphingolipid	JCR Pharmaceuticals
24	Condoliase (Seikagaku corporation)	GAG	Seikagaku, Kaken Pharmaceutical Co., Ltd., Ferring Pharmaceuticals
25	Burosumab-twza	FGF23	Kyowa Hakko Kirin, Ultragenyx
26	Damoctocog alfa pegol	F10	Bayer
27	Mecapegfilgrastim	CSF3R	Jiangsu Hengrui
28	Pegfilgrastim biosimilar (Cinfa Biotech)	CSF3R	Cinfa Biotech, Mundipharma
29	Pegfilgrastim biosimilar (Sandoz)	CSF3R	Sandoz
30	Pegfilgrastim-cbqv (Coherus BioSciences)	CSF3R	Coherus Biosciences
31	Pegfilgrastim-jmdb	CSF3R	Biocon, Mylan
32	Fremanezumab	CGRP	Pfizer, Teva
33	Galcanezumab	CGRP	Eli Lilly
34	Ibalizumab-uiyk	CD4	Biogen, TaiMed Biologics, Theratechnologies
35	Moxetumomab pasudotox	CD22	AstraZeneca
36	Erenumab-aooe	CALCRL	Amgen, Novartis
37	Ravulizumab	C5	Alexion Pharmaceuticals
38	Calaspargase pegol	ASN	Shire, Servier
39	Elapegademase-lvlr	Adenosine	Leadiant Biosci

According to the forecast of IMS Health, the Chinese biopharmaceutical market will become the world’s second largest biopharmaceutical market in 2020, only next to the U.S. Then, what are the forefronts in the process? How can pharmaceutical practitioners reach new heights?

Xuanyao, an independent observer of the pharmaceutical industry, with a master’s degree in Pharmacology from China Pharmaceutical University; having successively served in the Market Department of a listed pharmaceutical enterprise in China and Marketing Department of a Global 500 foreign enterprise; currently engaging in the pharmaceutical private equity investment industry, with the WeChat account: pharmacology_cpu

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.

Previous:Will Other Pharmaceutical Enterprises Follow Up after the Large-scale Acquisitions of “New Takeda” and “New BMS” that may Yield Successful Results?

Next:Evolving World of Pharma: Staying up to date with GMP

Analysis of 39 New Biological Drugs Marketed in the World in 2018

Related News

Has the booming PD-1 inhibitor reached its limit?

Future Prospects of Small Molecule and Monoclonal Antibody Drugs in Oncology and Immunology

What Sparks Will Come from the Collaboration Between CSPC and AstraZeneca?

Where Lies the Competitiveness of China's New Drugs for Central Nervous System?

You may like
More>>

Analysis of 39 New Biological Drugs Marketed in the World in 2018

Related News

Has the booming PD-1 inhibitor reached its limit?

Future Prospects of Small Molecule and Monoclonal Antibody Drugs in Oncology and Immunology

What Sparks Will Come from the Collaboration Between CSPC and AstraZeneca?

Where Lies the Competitiveness of China's New Drugs for Central Nervous System?

You may likeMore>>

You may like
More>>